表格類別： 股票 狀態： 新提交 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 公司名稱： 無錫藥明康德新藥開發股份有限公司 呈交日期： 2025年8月15日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫 ...

截止8月15日收盘，东北电气(00042)、弘业期货(03678)、安德利果汁(02218)分列AH溢价率前三位，溢 价率分别为770.97%、226.69%、213.19%；宁德时代(03750)、恒瑞医药(01276)、紫金矿业(02899)分列 AH溢价率末三位，溢价率分别为-19.95%、-7.45%、5.81%。其中安德利果汁(02218)、金力永磁 (06680)、南京熊猫电子股份(00553)的偏离值位居前三，分别为21.03%、11.03%、10.63%；另外，比亚 迪股份(01211)、东北电气(00042)、龙蟠科技(02465)的偏离值位居后三，分别 为-143.50%、-80.62%、-50.25%。 前十大AH股溢价率排行 前十大AH股偏离值排行 | 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↓ | | --- | --- | --- | --- | --- | | 安德利果汁(02218) | 18.350 | 47.98 | 213.19% | 21.03% | | 金力永磁(06680) | 19.090 | 28.17 | 76.74% | 11.03% | ...

Policy Developments - Qian'nan Prefecture's medical monitoring reported over 1,600 medical traceability rescues in the first half of the year, with 3.47 million residents insured, including 1.19 million special hardship groups [1] - Medical expenses for special hardship groups reached 282 million yuan, with reimbursements totaling 244 million yuan [1] Regulatory Changes - Tianjin's Medical Insurance Bureau proposed a new warning system for designated medical institutions, introducing yellow and red cards for non-compliance, which could lead to payment suspensions and contract terminations [2][3] Drug and Device Approvals - Qihuan Biotech's QT-019B CAR-T cell therapy received FDA approval for clinical trials, marking a significant milestone as the first universal CAR-T product developed by a Chinese company for autoimmune diseases [4] - Cloudtop's Acquimod NDA has been accepted in Taiwan, with peak sales potential estimated at 5 billion yuan, targeting moderate to severe ulcerative colitis [5] Financial Disclosures - China National Pharmaceutical Group reported a 10.43% decline in net profit for the first half of 2025, with revenues of 36.797 billion yuan [6] - Dongcheng Pharmaceutical's net profit fell by 20.7% to 88.65 million yuan, with revenues of 1.38 billion yuan [8] - Yangpu Medical reported a net profit of approximately 15.27 million yuan, with revenues down 21.22% to about 231 million yuan [9] Capital Market Activities - Hongxing Xianghe completed an A-round financing to enhance its innovative biopharmaceutical R&D efforts [10] - Silver诺药业-B saw a dark market surge of over 260%, with net proceeds from its global offering expected to reach approximately 610 million yuan [11] - Huaxi Biotech's controlling shareholder secured a loan commitment of up to 250 million yuan for share buybacks [12] - Nanmo Biotech's major shareholder increased its stake from 17.10% to 18.50% through market transactions [13] - WuXi AppTec repurchased 282,340 shares for approximately 27.99 million yuan as part of its buyback plan [14] Industry Developments - Wuxi City signed a strategic cooperation agreement with China National Pharmaceutical Group, emphasizing the importance of the biopharmaceutical industry for national security and economic development [15][16] Market Alerts - *ST Suwu's stock price fell below 1 yuan, risking delisting if it remains below this threshold for 20 consecutive trading days [17] - Aimeike's subsidiary REGEN Biotech Inc. is involved in a significant arbitration case with a claim of 1.6 billion yuan, affecting its financial outlook [18] - Sanyou Medical's actual controller plans to reduce their stake by up to 2% through block trades [19]

Group 1: Core Insights - Rongchang Biologics (09995.HK) announced that its innovative drug Taitasip (brand name: Tai Ai®) for treating primary Sjögren's syndrome has met the primary endpoint in a Phase III clinical trial in China [1] - Taitasip is the first BLyS/APRIL dual-target fusion protein drug to complete Phase III research in the field of Sjögren's syndrome globally [1] - The clinical trial was a multi-center, randomized, double-blind, placebo-controlled study aimed at evaluating the efficacy and safety of Taitasip, with the primary endpoint being the change in ESSDAI score at week 24 compared to baseline [1] Group 2: Disease Background and Drug Mechanism - Sjögren's syndrome is a chronic inflammatory autoimmune disease characterized by lymphocytic infiltration and damage to exocrine glands, leading to persistent dry mouth and dry eyes, and can affect multiple organ systems [2] - The prevalence of Sjögren's syndrome in China is estimated to be between 0.3% and 0.7%, with an increasing trend indicating a significant unmet clinical need [2] - Taitasip is a novel dual-target fusion protein developed by the company that simultaneously inhibits the overexpression of BLyS and APRIL, effectively preventing abnormal differentiation and maturation of B cells [2] Group 3: Regulatory and Clinical Recognition - Taitasip has received multiple authoritative guideline recommendations in China, including the "Clinical Practice Guidelines for Sjögren's Syndrome" and the "Expert Consensus on B-cell Targeted Therapy for Rheumatic and Immune Diseases" [2] - Internationally, Taitasip has been granted Fast Track designation by the U.S. FDA for its indication in Sjögren's syndrome and has been approved to conduct global multi-center Phase III clinical trials [2]

Summary of WuXi AppTec Conference Call Company Overview - WuXi AppTec is a leading global provider in the small molecule Contract Research, Development, and Manufacturing Organization (CRDMO) sector, with a revenue scale exceeding 40 billion yuan and a market share of approximately 8%-9% globally, which is expected to double in the future [2][29]. Financial Performance - The company is projected to achieve revenues of 42.5 to 43.5 billion yuan in 2025, reflecting a mid-double-digit growth rate, with an adjusted net profit margin expected to improve [2][9]. - The adjusted net profit margin reached 30% in the first half of 2025, driven by revenue structure optimization and cost reduction efforts [2][11]. - Capital expenditures are anticipated to be between 7 to 8 billion yuan in 2025, focusing on overseas markets and new molecular businesses, particularly peptides [2][10]. Business Segments - The chemical segment continues to be the core revenue and profit source, with its revenue share increasing to nearly 80% by 2024 and expected to rise further in 2025 [2][15]. - The small molecule CLDMO integrated business model covers the entire chain from drug discovery to commercial production, with early R&D contributing 20% of revenue, small molecule CDMO accounting for 62%, and rapidly growing peptide business reaching 20% [2][16]. Market Dynamics - The company has maintained a growth trajectory despite geopolitical risks, such as US-China tariffs, which have had limited actual impact on operations [2][7][13]. - The peptide business is a key growth driver, with expected revenue growth exceeding 80% in 2025, supported by demand for GLP-1 class products [2][19]. Operational Challenges - The testing business has faced challenges due to intense domestic competition, leading to a decline in revenue and gross margins [2][20][21]. - The clinical CRO and SMO sectors are experiencing significant competitive pressure, particularly in the CRO space, which has seen a 15% decline in revenue [2][23]. Future Outlook - WuXi AppTec is expected to continue its upward trajectory, with a strong order backlog and anticipated revenue growth of over 30% in 2025 [2][27]. - The company is well-positioned to capitalize on the global small molecule CMO market, with significant capital investments planned to enhance production capacity [2][31][32]. Key Risks - Geopolitical risks, particularly related to tariffs and regulations affecting Chinese suppliers, remain a concern but are being managed effectively [2][6][7]. - The company’s personnel size is expected to shrink in 2025 due to business divestitures, yet it will maintain the largest technical team globally [2][14]. Conclusion - WuXi AppTec is poised for robust growth driven by its strategic focus on high-demand sectors, effective management of geopolitical risks, and a strong operational foundation, making it a key player in the CRDMO industry [2][32].

公司名稱： 無錫藥明康德新藥開發股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年8月14日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | A | 於香港聯交所上市 | 否 | | | 證券代號 (如上市) | | 說明 | 於上海證券交易所上市 | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫 ...

药明康德（603259）(02359)发布公告，于2025年8月14日该公司斥资人民币2799.11万元回购28.23万股A 股，回购价格为每股人民币97.55-102.23元。 ...

Group 1 - WuXi AppTec (02359.HK) announced a share buyback plan on August 14, 2025, with a total expenditure of 27.9911 million RMB to repurchase 282,300 A-shares [1] - The buyback price per share ranges from 97.55 to 102.23 RMB [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 第 2 頁 共 12 頁 v 1.3.0 FF305 | 7). | 購回股份(或其他證券)但沒有註銷 | 282,748 | 0.01 % | RMB | 70.77 | | --- | --- | --- | --- | --- | --- | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 | | | | | | | 通函，及於2025年4月29日刊發的投票結果公告。 | | | | | | | 於2025年7月4日，本公司實施2025年第一次回購，并回購282,748股A | | | | | | | 股股份。 | | | | | | | 變動日期 2025年7月4日 | | | | | | 8). | 購回股份(或其他證券)但沒有註銷 | 287,026 | | | | | | | | 0.01 % | RMB | 69.71 | | | 茲提述本公司於2025年3月17日刊發的公告，於2025年3月26日刊發的 通函，及於2 ...

高盛主要观点如下： 资金流向上 —— 高盛的交易平台买入呈现 1.2 倍净卖出状态。消费和科技板块是平台最活跃的主题(双 向交易并存，但消费股更适合卖出而科技股更宜买入)。消费板块呈现双向流动，餐饮类股遭遇部分抛 售，而普拉达等零售股则买卖交投活跃。科技板块中，持续在硬科技领域获得买单，但对腾讯音乐等冲 高个股转为卖出。网易也获得较大力度买入。医疗保健 / 制药板块更受青睐 —— 翰森制药虽呈双向交 易但买方更占优势。 香港股市创下自五月初以来的最佳单日表现。 从行业板块来看，医疗保健、科技和消费板块领涨 —— 在中国政府宣布对符合条件的个人消费贷款实 施贴息计划后，国内零售商与消费医疗企业的股价应声上扬。医疗板块中，信达生物(+9%)、药明康德 (+6.2%)、翰森制药(+5.4%)涨幅居前。科技板块以腾讯音乐(+15.6%)表现最为亮眼，其财报大幅超出预 期，多家投行同步上调目标价。其他涨幅显著的个股包括阿里巴巴(+6.1%)、哔哩哔哩(+7.4%)，华虹半 导体(+5.9%)等芯片股亦表现强势。能源与电信板块表现滞后，虽维持涨势但明显跑输大盘，部分资金 正轮动至成长股。 智通财经APP获悉，高盛发布研报 ...